Caris Life Sciences, Inc. (CAI) financial statements and ratios from SEC XBRL: revenue $1.0B (TTM), net margin -8.4%, revenue growth 45.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $812.03M |
| Revenue (TTM) | $1.0B |
| Net Margin | -8.4% |
| Operating Margin (TTM) | 15.5% |
| Net Debt / EBITDA | -2.5 |
| Revenue Growth (YoY) | 45.4% |
| EPS Growth (YoY) | -100.0% |
| FCF Growth (YoY) | -323.9% |
| EV / EBITDA | 119.1 |
| Price / Book | 13.37 |
| Price / Sales | 9.01 |
| FCF Yield | 1.1% |
| Altman Z-Score | 7.27 (safe) |
| Industry P/E (Healthcare Services) | 25.4 |
| Sector P/E (Healthcare) | 21.9 |
CAI overview · CAI earnings · CAI KPIs · CAI documents · CAI ownership · CAI peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.